Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics
The expression “immunogenic cell death” (ICD) refers to a functionally unique form of cell death that facilitates (instead of suppressing) a T cell-dependent immune response specific for dead cell-derived antigens. ICD critically relies on the activation of adaptive responses in dying cells, culmina...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2017-12-01
|
| Series: | OncoImmunology |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/2162402X.2017.1386829 |
| _version_ | 1818458462664785920 |
|---|---|
| author | Abhishek D. Garg Sanket More Nicole Rufo Odeta Mece Maria Livia Sassano Patrizia Agostinis Laurence Zitvogel Guido Kroemer Lorenzo Galluzzi |
| author_facet | Abhishek D. Garg Sanket More Nicole Rufo Odeta Mece Maria Livia Sassano Patrizia Agostinis Laurence Zitvogel Guido Kroemer Lorenzo Galluzzi |
| author_sort | Abhishek D. Garg |
| collection | DOAJ |
| description | The expression “immunogenic cell death” (ICD) refers to a functionally unique form of cell death that facilitates (instead of suppressing) a T cell-dependent immune response specific for dead cell-derived antigens. ICD critically relies on the activation of adaptive responses in dying cells, culminating with the exposure or secretion of immunostimulatory molecules commonly referred to as “damage-associated molecular patterns”. Only a few agents can elicit bona fide ICD, including some clinically established chemotherapeutics such as doxorubicin, epirubicin, idarubicin, mitoxantrone, bleomycin, bortezomib, cyclophosphamide and oxaliplatin. In this Trial Watch, we discuss recent progress on the development of ICD-inducing chemotherapeutic regimens, focusing on studies that evaluate clinical efficacy in conjunction with immunological biomarkers. |
| first_indexed | 2024-12-14T22:58:51Z |
| format | Article |
| id | doaj.art-bba41788dd6d49e3ae68f6677950b756 |
| institution | Directory Open Access Journal |
| issn | 2162-402X |
| language | English |
| last_indexed | 2024-12-14T22:58:51Z |
| publishDate | 2017-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | OncoImmunology |
| spelling | doaj.art-bba41788dd6d49e3ae68f6677950b7562022-12-21T22:44:31ZengTaylor & Francis GroupOncoImmunology2162-402X2017-12-0161210.1080/2162402X.2017.13868291386829Trial watch: Immunogenic cell death induction by anticancer chemotherapeuticsAbhishek D. Garg0Sanket More1Nicole Rufo2Odeta Mece3Maria Livia Sassano4Patrizia Agostinis5Laurence Zitvogel6Guido Kroemer7Lorenzo Galluzzi8Cell Death Research & Therapy (CDRT) LabCell Death Research & Therapy (CDRT) LabCell Death Research & Therapy (CDRT) LabCell Death Research & Therapy (CDRT) LabCell Death Research & Therapy (CDRT) LabCell Death Research & Therapy (CDRT) LabGustave Roussy Comprehensive Cancer InstituteUniversité Paris Descartes/Paris VUniversité Paris Descartes/Paris VThe expression “immunogenic cell death” (ICD) refers to a functionally unique form of cell death that facilitates (instead of suppressing) a T cell-dependent immune response specific for dead cell-derived antigens. ICD critically relies on the activation of adaptive responses in dying cells, culminating with the exposure or secretion of immunostimulatory molecules commonly referred to as “damage-associated molecular patterns”. Only a few agents can elicit bona fide ICD, including some clinically established chemotherapeutics such as doxorubicin, epirubicin, idarubicin, mitoxantrone, bleomycin, bortezomib, cyclophosphamide and oxaliplatin. In this Trial Watch, we discuss recent progress on the development of ICD-inducing chemotherapeutic regimens, focusing on studies that evaluate clinical efficacy in conjunction with immunological biomarkers.http://dx.doi.org/10.1080/2162402X.2017.1386829antigen-presenting cellautophagycytotoxic t lymphocyteendoplasmic reticulum stressdamage-associated molecular patterndendritic cellimmune checkpoint blockertype i interferon |
| spellingShingle | Abhishek D. Garg Sanket More Nicole Rufo Odeta Mece Maria Livia Sassano Patrizia Agostinis Laurence Zitvogel Guido Kroemer Lorenzo Galluzzi Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics OncoImmunology antigen-presenting cell autophagy cytotoxic t lymphocyte endoplasmic reticulum stress damage-associated molecular pattern dendritic cell immune checkpoint blocker type i interferon |
| title | Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics |
| title_full | Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics |
| title_fullStr | Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics |
| title_full_unstemmed | Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics |
| title_short | Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics |
| title_sort | trial watch immunogenic cell death induction by anticancer chemotherapeutics |
| topic | antigen-presenting cell autophagy cytotoxic t lymphocyte endoplasmic reticulum stress damage-associated molecular pattern dendritic cell immune checkpoint blocker type i interferon |
| url | http://dx.doi.org/10.1080/2162402X.2017.1386829 |
| work_keys_str_mv | AT abhishekdgarg trialwatchimmunogeniccelldeathinductionbyanticancerchemotherapeutics AT sanketmore trialwatchimmunogeniccelldeathinductionbyanticancerchemotherapeutics AT nicolerufo trialwatchimmunogeniccelldeathinductionbyanticancerchemotherapeutics AT odetamece trialwatchimmunogeniccelldeathinductionbyanticancerchemotherapeutics AT marialiviasassano trialwatchimmunogeniccelldeathinductionbyanticancerchemotherapeutics AT patriziaagostinis trialwatchimmunogeniccelldeathinductionbyanticancerchemotherapeutics AT laurencezitvogel trialwatchimmunogeniccelldeathinductionbyanticancerchemotherapeutics AT guidokroemer trialwatchimmunogeniccelldeathinductionbyanticancerchemotherapeutics AT lorenzogalluzzi trialwatchimmunogeniccelldeathinductionbyanticancerchemotherapeutics |